ana paula bueno

Prof. ana paula bueno

Universidade Federal do Rio de Janeiro, Rio de Janeiro, Brazil

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 November 2017 in Head and Neck Pathology
Verified
Journal Article
Closed access
PDF file
NBNatália Rocha Bedran
Natália Rocha Bedran
RCRomán Carlos
Román Carlos
BABruno Augusto Benevenuto de Andrade
Bruno Augusto Benevenuto de Andrade
ABana paula bueno
ana paula bueno
MRMário José Romañach
Mário José Romañach
CMCristiane Milito
Cristiane Milito

23 September 2021 in Genes
Verified
Journal Article
Open access
PDF file
Bárbara ReisBárbara Reis
Bárbara Reis
DCDaniela Cunha
Daniela Cunha
ABana paula bueno
ana paula bueno
FCFLAVIA AMENDOLA ANISIO CARVALHO
FLAVIA AMENDOLA ANISIO CARVALHO
JDJuliana Teixeira Dutra
Juliana Teixeira Dutra
Zilton VasconcelosZilton Vasconcelos
Zilton Vasconcelos
Chronic Granulomatous Disease (CGD) is an inborn error of immunity characterized by impaired phagocyte function, recurrent fungal and bacterial infections and granuloma formation in multiple organs. Pediatric myelodysplastic Syndrome (MDS) is a rare hematological stem cell disease that leads to an ineffective hematopoiesis with variable risk of evolution to acute leukemias. Both disorders are rare and have distinct pathophysiologic mechanisms, with no known association. A 7-month-old boy presenting with recurrent infections and anemia at age 2 months underwent immunological, hematological and genetic investigation that culminated in the diagnosis of both CGD and MDS. Next generation sequencing was performed and identified a silent variant predicted as of Uncertain Significance, located in the splicing site at the end of exon 5 in CYBB. CYBB variants account for at least two thirds of CGD cases, but no previous descriptions of this variant were found in ClinVar or The Human Gene Mutation Database (HGMD) databases. We were able to demonstrate an exon 5 skipping on the proband’s cDNA, which strongly suggests the disruption of the NADPH oxidase complex, abrogating the formation of reactive oxygen species from neutrophils. Moreover, erythroid cell lineage could be also affected by NADPH oxidase complex damages. Further investigation is needed to evaluate the potential effect of CYBB gene alterations in hematopoiesis, as well as in MDS and CGD association.

28 April 2023 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
VLViviane Lamim Lovatel
Viviane Lamim Lovatel
ABana paula bueno
ana paula bueno
EKElaiza Almeida Antônio de Kós
Elaiza Almeida Antônio de Kós
LMLaura Guimarães Corrêa Meyer
Laura Guimarães Corrêa Meyer
GFGerson Moura Ferreira
Gerson Moura Ferreira
TFTeresa de Souza Fernandez
Teresa de Souza Fernandez
Background: Childhood myelodysplastic neoplasm (cMDS) often raises concerns about an underlying germline predisposition, and its verification is necessary to guide therapeutic choice and allow family counseling. Here, we report a novel constitutional t(3;8)(p26;q21) in a child with MDS, inherited from the father, the ANKRD26 and SRP72 variants from the maternal origin, and the acquisition of molecular alterations during MDS evolution. Case presentation: A 4-year-old girl showed repeated infections and severe neutropenia. Bone marrow presented hypocellularity with dysplastic features. The patient had a t(3;8)(p26;q21)c identified by G-banding and FISH analysis. The family nucleus investigation identified the paternal origin of the chromosomal translocation. The NGS study identified ANKRD26 and SRP72 variants of maternal origin. CGH-array analysis detected alterations in PRSS3P2 and KANSL genes. Immunohistochemistry showed abnormal p53 expression during the MDS evolution. Conclusion: This study shows for the first time, cytogenetic and genomic abnormalities inherited from the father and mother, respectively, and their clinical implications. It also shows the importance of investigating patients with constitutional cytogenetic alterations and/or germline variants to provide information to their family nucleus for genetic counseling and understanding of the pathogenesis of childhood MDS.

1 January 2024 in Mediterranean Journal of Hematology and Infectious Diseases
Verified
Journal Article
Open access
PDF file
VLViviane Lamim Lovatel
Viviane Lamim Lovatel
BSBeatriz Ferreira da Silva
Beatriz Ferreira da Silva
EREliane Ferreira Rodrigues
Eliane Ferreira Rodrigues
MBMaria Luiza Rocha da Rosa Borges
Maria Luiza Rocha da Rosa Borges
RTRita de Cássia Barbosa Tavares
Rita de Cássia Barbosa Tavares
TFTeresa de Souza Fernandez
Teresa de Souza Fernandez
Background and objective: Pediatric myelodysplastic syndrome (pMDS) is a group of rare clonal neoplasms with a difficult diagnosis and risk of progression to acute myeloid leukemia (AML). The early stratification in risk groups is essential to choosing the treatment and indication for allogeneic hematopoietic stem cell transplantation (HSCT). According to the Revised International Prognostic Scoring System, cytogenetic analysis has demonstrated an essential role in diagnosis and prognosis. In pMDS, abnormal karyotypes are present in 30-50% of the cases. Monosomy 7 is the most common chromosomal alteration associated with poor prognosis. However, the rarity of specific cytogenetic alterations makes its prognosis uncertain. Thus, this study aimed to describe uncommon cytogenetic alterations in a cohort of 200 pMDS patients and their association with evolution to AML. Methods: The cytogenetic analysis was performed in 200 pMDS patients by G-banding and fluorescence in situ hybridization between 2000 to 2022. Results: Rare chromosome alterations were observed in 7.5% (15/200) of the cases. These chromosome alterations were divided into four cytogenetic groups: hyperdiploidy, biclonal chromosomal alterations, translocations, and uncommon deletions, which represented 33.3%, 33.3%, 20%, and 13.3%, respectively. Most of these patients (10/15) were classified with advanced MDS (MDS-EB and MDS/AML) and the initial subtype was present in five patients (RCC). The leukemic evolution was observed in 66.66% (10/15) of the patients. Most patients had poor clinical outcomes and they were indicated for HSCT.  Conclusion: The study of uncommon cytogenetic alterations in pMDS is important to improve the prognosis and guide early indication of HSCT. Keywords: Pediatric MDS; Leukemic evolution; rare chromosomal altwerations; HSCT, Children

1 September 2021 in Pediatric Hematology Oncology Journal
Verified
Journal Article
Open access
DCDiego F. Coutinho
Diego F. Coutinho
MBMariana Boroni
Mariana Boroni
ABAnna Beatriz W. Batalha
Anna Beatriz W. Batalha
DVDanielle T. Vianna
Danielle T. Vianna
MKMayara Kalonji
Mayara Kalonji
IZIlana R. Zalcberg
Ilana R. Zalcberg

28 November 2025 in Biomedicines
Verified
Journal Article
Open access
PDF file
BSBeatriz Ferreira da Silva
Beatriz Ferreira da Silva
VLViviane Lamim Lovatel
Viviane Lamim Lovatel
GLGabriela Farias Lima
Gabriela Farias Lima
GRGiulia Miceli Giglio Rodrigues
Giulia Miceli Giglio Rodrigues
MBMaria Luiza Rocha da Rosa Borges
Maria Luiza Rocha da Rosa Borges
TFTeresa de Souza Fernandez
Teresa de Souza Fernandez
Background/Objectives: Pediatric myelodysplastic syndrome (pMDS) is a rare, heterogeneous, clonal hematopoietic stem cell disease with a risk of evolution to acute myeloid leukemia (AML). Clonal cytogenetic abnormalities are present in 30–60% of pMDS. However, unlike in adults, the prognostic significance of chromosomal alterations, particularly their role in predicting evolution to AML, remains limited in pMDS. To acknowledge this gap, we studied the cytogenetic abnormalities in pMDS and analyzed their associations with subtypes and evolution to AML. Furthermore, in the Discussion Section, we pointed out key genes involved in these chromosomal alterations. Methods: Cytogenetic analysis was performed on 193 pediatric patients using G-banding and fluorescence in situ hybridization. Results: Abnormal karyotypes were observed in 43.5% (84/193) of patients, mainly in the advanced subtype. The main chromosomal alterations were monosomy 7 (−7) in 14% of the cases (12/84), deletion of the long arm of chromosome 11 [del(11q)] in 12% (10/84) and both trisomy 8 (+8) and deletion of the long arm of chromosome 7 [del(7q)] in 8% (7/84). Evolution from MDS to AML was observed in 22% of the patients (42/193), and it was associated with complex karyotypes, del(11q), −7/del(7q), and +8. Conclusions: Our results suggest that specific chromosomal alterations, such as del(11q), del(7q), and +8, may predict evolution to AML and might be considered high-risk cytogenetic markers in pMDS.